XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.3
INTANGIBLE ASSETS AND GOODWILL (Tables)
 9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of net-book value and estimated remaining life and finite lived intangible assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2025:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at September 30, 2025
Finite-lived intangible assets
Acquired developed technology
5.8$887,498 $(474,965)$412,533 
Trade name10.1104,000 (40,590)63,410 
Patents and licenses8.859,492 (16,568)42,924 
Customer relationships5.34,000 (1,667)2,333 
Total finite-lived intangible assets1,054,990 (533,790)521,200 
In-process research and developmentn/a420,000 — 420,000 
Total intangible assets$1,474,990 $(533,790)$941,200 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2024:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at December 31, 2024
Finite-lived intangible assets
Acquired developed technology
6.4$887,104 $(412,504)$474,600 
Trade name10.8104,000 (35,153)68,847 
Patents and licenses9.556,542 (12,963)43,579 
Customer relationships6.04,000 (1,333)2,667 
Total finite-lived intangible assets1,051,646 (461,953)589,693 
In-process research and developmentn/a420,000 — 420,000 
Total intangible assets$1,471,646 $(461,953)$1,009,693 
Schedule of estimated future amortization expense, intangible assets
As of September 30, 2025, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2025 (remaining three months)$24,164 
202695,659 
202795,659 
202895,659 
202989,536 
Thereafter120,523 
$521,200 
Schedule of carrying amount of goodwill
The change in the carrying amount of goodwill for the periods ended September 30, 2025 and December 31, 2024 is as follows:
(In thousands)
Balance, January 1, 2024
$2,367,120 
Resolution Bioscience acquisition adjustments225 
Effects of changes in foreign currency exchange rates
(669)
Balance, December 31, 2024
2,366,676 
Effects of changes in foreign currency exchange rates
1,352 
Balance, September 30, 2025
$2,368,028